Harvard Bioscience, Inc.
HBIO
$0.489
$0.01292.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -6.08% | -11.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -6.08% | -11.33% | |||
| Cost of Revenue | -7.02% | -8.68% | |||
| Gross Profit | -5.34% | -13.31% | |||
| SG&A Expenses | -13.34% | 1.46% | |||
| Depreciation & Amortization | 0.17% | -7.72% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.95% | -2.90% | |||
| Operating Income | 61.88% | -453.81% | |||
| Income Before Tax | 95.56% | -8,709.15% | |||
| Income Tax Expenses | 106.17% | -179.37% | |||
| Earnings from Continuing Operations | 95.47% | -279,766.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 95.47% | -279,766.67% | |||
| EBIT | 61.88% | -453.81% | |||
| EBITDA | 3,116.13% | -98.60% | |||
| EPS Basic | 95.49% | -285,500.00% | |||
| Normalized Basic EPS | 25.64% | -211.43% | |||
| EPS Diluted | 95.49% | -285,500.00% | |||
| Normalized Diluted EPS | 25.64% | -213.70% | |||
| Average Basic Shares Outstanding | 0.47% | 1.00% | |||
| Average Diluted Shares Outstanding | 0.47% | -0.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||